Search

Displaying results 3461 - 3470 of 10000 in total
  1. Drug

    MVA3000

    go.drugbank.com/drugs/DB05040
    Experimental

    MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or

  2. Drug

    Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10296
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … * serotype 6a individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197).

    Mixtures: PREVENAR 13 SUSPENSION FOR INJECTIONSynonyms: Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine, Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
  3. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. … Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.

    Categories: Heterocyclic Compounds with 4 or More Rings
  4. Drug

    Lufotrelvir

    go.drugbank.com/drugs/DB16514
    Investigational

    PF-07304814 is a small molecule prodrug that targets the 3CL<sup>pro</sup> protease (M<sup>pro)</sup>, which is used by viruses like SARS-CoV-2 to assemble and multiply[L31718]. … on preprint servers[L31733, L31125].

    Categories: Experimental Unapproved Treatments for COVID-19
  5. Drug

    Cyd dengue virus serotype 1 live (attenuated) antigen

    go.drugbank.com/drugs/DB15521
    ApprovedInvestigationalWithdrawn

    Mixtures: DENGVAXIA MD, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION, DENGVAXIA, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION
  6. Drug

    Cyd dengue virus serotype 2 live (attenuated) antigen

    go.drugbank.com/drugs/DB15522
    ApprovedInvestigationalWithdrawn

    Mixtures: DENGVAXIA MD, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION, DENGVAXIA, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION
  7. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  8. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is being developed by Rinat and is currently in Phase I clinical trials. … RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain.

  9. Drug

    Cyclopentamine

    go.drugbank.com/drugs/DB08999
    ApprovedWithdrawn

    Cyclopentamine is a sympathomimetic alkylamine, classified as a vasoconstrictor. Cyclopentamine was an over the counter treatment for nasal congestion in Europe and Australia. … It has been widely discontinued due to the safety, effectiveness, and availability of a similar drug, propylhexedrine.

  10. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    of patients with idiopathic myelofibrosis or essential thrombocythemia. … Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index